EMA validates Immunome’s MAA for varegacestat, an oral, once-daily gamma secretase inhibitor to treat adults with desmoid tumours: Bothell, Washington Monday, November 2, 2026, ...
Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer ...
Immunome (IMNM) news covers targeted oncology programs, varegacestat for desmoid tumors, ADC and radiotherapy pipeline updates, and stock grants. Latest IMNM news updated today, November 2.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results